China Aoxing Pharmaceutical Company Honorably Awarded Center of Excellence in Enterprise Technology by Consortium of China Gover
24 September 2009 - 10:00PM
Marketwired
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China
Aoxing"), a China-based pharmaceutical company specializing in
research, development, manufacturing and distribution of narcotic
and pain-management products, today announced that China Aoxing
honorably received Center of Excellence Award in Enterprise
Technology by the consortium of China local government offices.
China Aoxing, along with thirteen other companies across several
industry sectors, became the recipient of the award jointly by the
Development and Reform Commission of Shijiazhuang City, Finance
Bureau of Shijiazhuang City, and Taxation Bureau of Shijiazhuang
City. The selection criteria were based on demonstrated systemic
excellence and competitiveness in product quality, technology,
environmental protection as well as technical credential of
management leadership. The government will provide financial
support and business enhancement to the recipients on an annual
basis.
"The Center of Excellence Award celebrates the product quality
and technology management which is part of the fabric of our
business, and we are much honored to receive this recognition with
the other two distinguished pharmaceutical companies given the fact
that there are over a hundred well-established pharmaceutical
companies under the consideration of our city government. This
award exemplifies our product quality, innovation culture and
highest values and standard embraced within our company. We will
continue focusing on quality management and technological
competitiveness, and creating greater value for investors,"
commented by Mr. Zhenjiang Yue, the Chairman and CEO of China
Aoxing.
About China Aoxing Pharmaceutical Company, Inc.
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a
pharmaceutical company located in China specializing in research,
development, manufacturing and distribution of a variety of
narcotics and pain-management products. It has a strategic alliance
with American Oriental Bioengineering, Inc. (NYSE: AOB) to develop
and market various narcotic drugs in China. Headquartered in
Shijiazhuang City, the pharmaceutical capital of China, outside of
Beijing, China Aoxing has China's largest and the most advanced
manufacturing facility for highly regulated narcotic medicines,
addressing a very under-served and fast-growing market in China.
Its facility is one of the few GMP facilities licensed for
narcotics medicines. The Company is working closely with the
Chinese government and SFDA to assure the strictly regulated
availability to medical professionals of its narcotic drugs and
pain medicines throughout China.
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks and
uncertainties that may cause actual results to differ materially
from those set forth in these statements. The economic,
competitive, governmental, technological and other risk factors
identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-KSB for the year ended
June 30, 2008, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
Contact: Wei Zhang China Aoxing Pharmaceutical Company, Inc.
Email: chinaaoxing@gmail.com Telephone: 646-367-1747 Website:
www.chinapainmed.com
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024